epirubicin


Also found in: Wikipedia.

epirubicin

 [ep″e-roo´bĭ-sin]
an antitumor antibiotic of the anthracycline group, having the same actions as doxorubicin but a lower toxicity; administered intravenously in the treatment of carcinoma of the breast, ovary, stomach, colon, and rectum, as well as leukemia, lymphoma, and multiple myeloma.

epirubicin

/epi·ru·bi·cin/ (-roo´bĭ-sin) an antineoplastic with action similar to doxorubicin; used in the treatment of various carcinomas, leukemia, lymphoma, and multiple myeloma.

epirubicin

an antibiotic antineoplastic.
indications It is used as an adjuvant therapy to treat breast cancer with axillary node involvement following resection.
contraindications Factors that prohibit its use include severe hepatic disease, baseline neutrophil count less than 1500 cells/mm3, severe myocardial insufficiency, recent myocardial infarction, pregnancy, lactation, systemic infections, and known hypersensitivity to this drug, anthracyclines, or anthracenediones.
adverse effects Life-threatening effects are thrombocytopenia, leukopenia, anemia, neutropenia, secondary acute myelocytic leukemia, sinus tachycardia, premature ventricular contractions, bradycardia, and extrasystoles. Other serious adverse effects include increased blood pressure and chest pain. Common side effects include nausea, vomiting, anorexia, mucositis, diarrhea, amenorrhea, hot flashes, hyperuricemia, rash, necrosis at the injection site, reversible alopecia, infection, febrile neutropenia, lethargy, fever, and conjunctivitis.

epirubicin

A CYTOTOXIC anti-cancer drug. A brand name is Pharmorubicin.

epirubicin

an anthracycline antibiotic similar to doxorubicin, used as an antineoplastic agent.
References in periodicals archive ?
In the neoadjuvant phase, enrolled patients received run-in chemotherapy consisting of epirubicin and cyclophosphamide every three weeks for four cycles.
The only reported case when given chemotherapy based on epirubicin, trastuzumab, and cyclophosphamide; tolerated it well up to 3 cycles.
5 FOLFOX 0 IAP 0 ABVD: Adriamycin, bleomycin, vinblastine, dacarbazine, ICE: Ifosfamide, carboplatin, etoposide, ECF: Epirubicin, cisplatin, 5-fluorouracil, FEC: 5-fluorouracil, epirubicin, cyclophosphamide, IA: Idarubicin, Cytarabine, CHOP: Cyclophosphamide, hydroxyl-daunorubicin, oncovin, prednisone, FOLFOX: Fluorouracil, leucovorin, oxaliplatin, IAP: Oxaliplatin, epirubicin, ifosfamide Table 3: Adverse effects in study subjects Adverse n (%) effects Interventional group Non-interventional group Nausea 0 1 (5) Diarrhea 3 (15) 4 (20) Dizziness 2 (10) 1 (5) Vomiting 3 (15) 5 (25) Headache 2 (10) 2 (10) Dysgeusia 4 (20) 2 (10)
The patient was treated with four cycles of neoadjuvant chemotherapy of TEC regime (Docetaxel 75 mg/m [sup]2, Epirubicin 75 mg/m [sup]2, and cyclophosphamide 500 mg/m [sup]2) every 3 weeks, followed by modified radical mastectomy.
Both were taken after another chemotherapy drug, named epirubicin.
Cardioxane is a cardioprotective agent used to prevent chronic cumulative cardiotoxicity caused by doxorubicin or epirubicin in advanced and/or metastatic adult breast cancer patients who have received a prior cumulative dose of 300mg/m2 of doxorubicin or 540mg/m2 of epirubicin when further chemotherapy treatment is required.
Bacillus Calmette-Guerin (BCG), mitomycin C, epirubicin, and doxorubicin are chemotherapy agents used for intravesical instillation (Shelley, Mason, & Kynaston, 2010).
The patient received six cycles of adjuvant chemotherapy FEC regimen (5-flurouracil, epirubicin, cyclophoshphamide) followed by radiation to the chest wall.
The CHOP regimen combined with HAART is the standard chemotherapy for A-NHL cases, mainly including cases of diffuse large B-cell lymphoma,28,29 and the addition of rituximab has a beneficial effect on high CD20-expressing patients,26,28 treated mainly with R-CHOP, R-CDE, and R-EPOCH (chemotherapy regimen including Rituxan, etoposide, prednisone, epirubicin, cyclophosphamide, and changchun sheen).
Chemotherapy regimens described in the literature have included FEC (fluorouracil, epirubicin, and cyclophosphamide), CMF (cyclophosphamide, methotrexate, and fluorouracil), adriamycin and cisplatin, paclitaxel alone, CAE (cyclophosphamide, doxorubicin, etoposide) and CP (cisplatin, etoposide) as single agents or in combinations.
Transferrin and epirubicin were attached with magnetic nanoparticles (MNPs) to deliver anti-cancer drug at target site (in vitro).
She received adjuvant chemotherapy in the form of three cycles of Fluorouracil, Epirubicin and Cyclophosphamide and 3 cycles of Docetaxel.